Also known as: Lys-Pro-Val · alpha-MSH(11-13)
KPV is a naturally occurring tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). It exhibits potent anti-inflammatory activity in gut and skin tissue through direct NF-κB suppression, without the systemic hormonal effects of the parent peptide.
KPV (Lysine-Proline-Valine) is a tripeptide fragment of the endogenous neuropeptide α-MSH, representing its biologically active C-terminal tripeptide sequence (positions 11–13). The parent peptide α-MSH is produced by the pituitary gland and exerts broad anti-inflammatory and immunomodulatory effects through MC1R binding.
Critically, KPV retains the full anti-inflammatory potency of α-MSH without binding to melanocortin receptors, meaning it produces no pigmentation, hormonal, or systemic side effects. It penetrates gut epithelium and inflamed tissue directly, making it a leading candidate for localized inflammatory bowel conditions. Oral delivery in nanoparticle carriers has shown particular promise in murine colitis models.
KPV directly inhibits the nuclear translocation of NF-κB p65, the master regulator of pro-inflammatory cytokine production. This blocks downstream expression of TNF-α, IL-1β, IL-6, and IL-8 in macrophages and intestinal epithelial cells.
Beyond cytokine suppression, KPV promotes tight junction protein expression (occludin, claudin-1), restoring gut barrier integrity that is compromised in IBD. It also reduces mast cell degranulation in inflamed mucosa.
KPV is exceptionally well-tolerated in preclinical models — its anti-inflammatory mechanism (NF-κB suppression via cAMP/PKA) does not produce the immunosuppression seen with corticosteroids. No significant systemic effects on HPA axis or melanogenesis at research doses. The Pro residue provides partial protease resistance compared to dipeptides, contributing to its relative oral activity.
KPV targets the NF-κB pathway rather than a peptide receptor that desensitizes — continuous use protocols are used in IBD models without evidence of tachyphylaxis. Cycle breaks are standard practice in research protocols. For acute inflammatory conditions (flare management), shorter higher-dose cycles are used; for maintenance, lower continuous doses.
Ask anything about KPV — mechanisms, dosing protocols, interactions, or research comparisons.
Thymosin Alpha-1 (Tα1) is the N-terminally acetylated 28-amino-acid peptide originally isolated from bovine thymus by Al…
Epithalon is a synthetic tetrapeptide analog of Epithalamin — a polypeptide extract of the pineal gland — developed by P…
Larazotide is a synthetic 8-amino-acid peptide derived from zonula occludens toxin (ZOT) from Vibrio cholerae. It acts a…